Pemirolast for Allergic Conjunctivitis

Author: Monica Preboth
Date: Oct 1, 2000

The U.S. Food and Drug Administration (FDA) has approved pemirolast potassium (Alamast) ophthalmic solution 0.1 percent, a new ocular allergy medication indicated for the prevention of itching associated with allergic conjunctivitis. Approximately 20 percent of persons in the United States have allergies, about 50 percent of whom require ocular medication for the relief of allergic symptoms.

Pemirolast is a mast cell stabilizer that inhibits the antigen-induced release of inflammatory mediators that are involved in the allergic process.

In clinical studies, side effects of pemirolast included foreign body sensation (2 percent), burning/stinging (1 percent), dry eye (1 percent) and ocular discomfort (1 percent). The manufacturer suggests that patients who wear soft contact lenses and whose eyes are not red should wait at least 10 minutes after using pemirolast before inserting contact lenses.

COPYRIGHT 2000 American Academy of Family PhysiciansCOPYRIGHT 2000 Gale Group

© 2006,, All Rights Reserved.